FTC Clears Kirin’s Acquisition Of Kyowa Hakko
This article was originally published in PharmAsia News
The U.S. Federal Trade Commission March 25 approved Japanese brewer Kirin Holdings' acquisition of pharmaceutical company Kyowa Hakko Kogyo Co. The FTC announced that it had reviewed the case and found no concerns regarding competition. Kirin Holding has been buying Kyowa's stock, and plans to increase its holdings to 50.1 percent by April 1. Kirin Pharmaceutical Co., the pharmaceutical business division of Kirin Holdings, is scheduled to merge with Kyowa Hakko on Oct. 1. (Click here for more-Japanese language
You may also be interested in...
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.